What is Nostos Genomics?
Nostos Genomics is at the forefront of leveraging artificial intelligence to interpret complex genetic information. The company's proprietary platform, AION, combines machine learning with functional genomics to meticulously characterize genetic mutations. This sophisticated approach automates the interpretation of genetic variants, translating raw genetic data into actionable insights for impactful clinical interventions. The company's focus on AI-driven genetic analysis positions it as a key player in the rapidly evolving field of precision medicine and genomic healthcare.
How much funding has Nostos Genomics raised?
Nostos Genomics has raised a total of $5.7M across 1 funding round:
Angel/Seed
$5.7M
Angel/Seed (2022): $5.7M with participation from Acequia Capital, Entrepreneur First, Amino Collective, 42cap, and Frontline Ventures
Key Investors in Nostos Genomics
Acequia Capital
Acequia Capital is a venture capital firm known for investing in early-stage technology companies, indicating a focus on foundational innovation.
Entrepreneur First
Entrepreneur First is an international Talent Investor that supports individuals in building technology companies, suggesting a focus on disruptive ventures and strong founding teams.
42cap
42CAP is a venture capital firm specializing in seed-stage tech and data-driven B2B software companies, particularly those with global ambitions, highlighting their interest in scalable technology solutions.
What's next for Nostos Genomics?
With this substantial strategic investment, Nostos Genomics is poised for accelerated growth and further development of its AI-powered genetic interpretation capabilities. The capital infusion is expected to fuel advancements in its AION platform, enhance its market penetration, and potentially expand its clinical applications. This funding round signals a strong market validation for Nostos Genomics' innovative approach to tackling genetic diseases, positioning the company for significant impact in the healthcare sector.
See full Nostos Genomics company page
